Results 81 to 90 of about 10,346 (205)
ACR Open Rheumatology, Volume 8, Issue 4, April 2026.Objective Gain‐of‐function variants in IDH1 and IDH2 are enriched among individuals with coexisting myeloid neoplasms and autoimmune diseases. However, the association between IDH1/IDH2 variants and rheumatic diseases independent of hematologic neoplasms remains unclear. We investigated the association between rare gain‐of‐function and loss‐of‐function
Mahmut S. Kaymakci +3 more
wiley +1 more source
Therapeutic advances in the treatment of vasculitis [PDF]
, 2016 Considerable therapeutic advances for the treatment of vasculitis of the young have been made in the past 10 years, including the development of outcome measures that facilitate clinical trial design.
Brogan, PA, Eleftheriou, D
core +2 more sources
Arthritis &Rheumatology, Volume 78, Issue 4, Page 970-975, April 2026.Objective Ear, nose, and throat (ENT) manifestations are common in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There is an unmet need for drugs to target these manifestations. Granuloma formation is characteristic of proteinase 3 (PR3)–AAV. In a zebrafish model, niclosamide inhibits PR3‐induced granuloma formation.
Benjamin Lim +4 more
wiley +1 more source
Clinical and Translational Allergy, Volume 16, Issue 4, April 2026.ABSTRACT Background As monoclonal antibodies have proven effective in managing recalcitrant chronic rhinosinusitis with nasal polyps (CRSwNP), the concept of disease remission is evolving, underscoring the need for a comprehensive, multimodal evaluation of disease burden over time.
Francesco Giombi +12 more
wiley +1 more source
What is new in the management of rapidly progressive glomerulonephritis? [PDF]
, 2015 Rapidly progressive glomerulonephritis (RPGN) results from severe crescentic damage to glomeruli and leads to irreversible kidney failure if not diagnosed and managed in a timely fashion.
Greenhall, GHB, Salama, AD
core +1 more source
DEN Open, Volume 6, Issue 1, April 2026.Abstract Direct oral anticoagulants (DOACs), including edoxaban, are widely used for stroke prevention in atrial fibrillation and venous thromboembolism. While gastrointestinal bleeding and diarrhea are recognized adverse effects, DOAC‐induced enterocolitis has not been established as a distinct clinical entity.
Katsuya Endo +8 more
wiley +1 more source
Intracerebral hemorrhage after IV tPA for stroke as early symptom of ANCA-associated vasculitis
eNeurologicalSci, 2017 Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are rare diseases characterized by a necrotizing small-vessel vasculitis and circulating ANCA that comprise granulomatosis with polyangiitis, microscopic polyangiitis, and ...
Neda Zarghami Esfahani +3 more
doaj +1 more source
Fulminant Wegener's granulomatosis: A case report [PDF]
, 2013 Introduction. Granulomatosis Wegener is anti-neutrophil cytoplasmic antibodies (ANCAs)-associated systemic vasculitis of unknown etiology. It is manifested as granulomatous necrotizing inflammation of the upper and lower parts of the respiratory tract,
Dinić Miroslav Ž. +3 more
core +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 4, April 2026.Abstract The effect of end‐stage kidney disease (ESKD) and hemodialysis (HD) on avacopan exposure is unknown. This Phase 1 study evaluated the pharmacokinetics (PK) and safety of avacopan and its active metabolite M1 in healthy participants and participants with ESKD requiring HD following a single 30‐mg oral dose administered with food.
Caroline Mohrmann +11 more
wiley +1 more source
MPO-ANCA-Associated Necrotizing Glomerulonephritis in Rheumatoid Arthritis; a Case Report and Review of Literature [PDF]
, 2017 BACKGROUND: Renal involvement in rheumatoid arthritis (RA) is common and has a negative impact on patient survival. Only few cases have been reported of necrotizing glomerulonephritis (GN) associated with myeloperoxidase anti-neutrophil cytoplasmic ...
Carvalho, D +6 more
core +1 more source